Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rIFN-gamma 1b adjunctive therapy for candidemia
2020-003204-13Phase 2Active
- Sponsor
- Radboudumc
- Start
- Aug 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of interferon gamma-1b in candidemia (2 arms), sponsored by Radboudumc. Primary endpoints: Time to first negative blood culture and Clearance of candidemia within 7 days taking mortality into account. Started Aug 2021; status: active.
02
Drugs
interferon gamma-1b
03
Conditions
candidemia
Beyond the preview
Go deeper on 2020-003204-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003204-13.